<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v3.0 20080202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing3.dtd?><?SourceDTD.Version 3.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Iran J Basic Med Sci</journal-id><journal-id journal-id-type="iso-abbrev">Iran J Basic Med Sci</journal-id><journal-id journal-id-type="publisher-id">IJBMS</journal-id><journal-title-group><journal-title>Iranian Journal of Basic Medical Sciences</journal-title></journal-title-group><issn pub-type="ppub">2008-3866</issn><issn pub-type="epub">2008-3874</issn><publisher><publisher-name>Mashhad University of Medical Sciences</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">IJBMS-17-531</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Evaluation of HTLV-1 activity in HAM/TSP patients using proviral load and Tax mRNA expression after <italic>In Vitro</italic> lymphocyte activation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Yari</surname><given-names>Atefeh</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Rezaee</surname><given-names>Seyyed Abdolrahim</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Valizadeh</surname><given-names>Narges</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Rajaee</surname><given-names>Taraneh</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Jazayeri</surname><given-names>Seyyed Mohammad</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Soltani</surname><given-names>Mojdeh</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Norouzi</surname><given-names>Mehdi</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib></contrib-group><aff id="aff1"><label>1</label> Microbiology and Virology Research Center, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran
</aff><aff id="aff2"><label>2</label> Immunology Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
</aff><aff id="aff3"><label>3</label> Inflammation and Inflammatory diseases Research Center, Faculty of Medicine, Mashhad University of Medical Science, Mashhad, Iran
</aff><aff id="aff4"><label>4</label> Virology Department, Public Health School, Tehran University of Medical Sciences, Tehran, Iran
</aff><author-notes><corresp id="cor1"><label>*</label><italic>Corresponding author:</italic> Mehdi Norouzi, Virology Department, Public Health School, Tehran University of Medical Sciences, Tehran, Iran. Tel: +98-22-66222668; email: <email>mnorouzi@tums.ac.ir</email></corresp></author-notes><pub-date pub-type="ppub"><month>7</month><year>2014</year></pub-date><volume>17</volume><issue>7</issue><fpage>531</fpage><lpage>536</lpage><history><date date-type="received"><day>29</day><month>7</month><year>2013</year></date><date date-type="accepted"><day>20</day><month>4</month><year>2014</year></date></history><permissions><copyright-statement>&#x000a9; Iranian Journal of Basic Medical Sciences</copyright-statement><copyright-year>2014</copyright-year><license><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title>Objective(s):</title><p>HTLV-1 is the first human retrovirus that has been recognized and is associated with HAM/TSP and ATLL. Studies have shown that less than five percent of HTLV-1 infected carriers develop HAM/TSP or ATLL and about ninety-five percent remain asymptomatic. Therefore, the proviral load with Tax may affect cellular genes such as cytokines and oncogenes, as well as involve in pathogenicity.</p></sec><sec><title>Materials and Methods:</title><p>Thirty HAM/TSP patients, thirty HTLV-1 healthy carriers, and MT-2 cell line were evaluated for HTLV-1 activity. PBMCs were isolated and activated using PMA and ionomycine. Real-time PCR and TaqMan methods were performed using specific primers and fluorescence probes for Tax expression and proviral load assessment. B2microglobulin (&#x003b2;<sub>2</sub>m) and albumin were used as controls in Tax expression and in proviral load, respectively.</p></sec><sec><title>Results:</title><p>An insignificant increase in Tax expression was observed in rest PBMCs of HAM/TSP patients compared to healthy carriers. However, after lymphocyte activation there was a significant increase in Tax expression in HAM/TSP patients (<italic>P</italic>=0.042). The Proviral load in patients was significantly higher than in carriers. Moreover, there was a significant correlation between Tax mRNA expression in activated PBMCs and proviral load (R=0.37, <italic>P</italic>=0.012).</p></sec><sec><title>Conclusion:</title><p>Although proviral load had been addressed as a valuable index for monitoring HTLV-1 infected subjects, the results of this study demonstrated that Tax expression in activated PBMCs along with proviral load assessment in HAM/TSP patients are a more reliable factor for determining the prognosis and monitoring healthy carriers and HAM/TSP patients.</p></sec></abstract><kwd-group><title>Keywords</title><kwd>Gene expression</kwd><kwd>HAM/TSP</kwd><kwd>HTLV-1</kwd><kwd>Proviral load</kwd><kwd>Tax mRNA</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Human T-cell leukemia virus type-1 (HTLV-1) is an oncogenic human retrovirus that causes diseases with different clinical outcomes such as adult T-cell leukemia/lymphoma (<xref rid="R1" ref-type="bibr">1</xref>, <xref rid="R2" ref-type="bibr">2</xref>), and inflammatory neurologic disease, mainly HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) (<xref rid="R3" ref-type="bibr">3</xref>, <xref rid="R4" ref-type="bibr">4</xref>). Other autoimmune diseases including sjogern's syndrome, polymyositis, inflammatory arthritis and uveitis might be associated with HTLV-1 infection (<xref rid="R5" ref-type="bibr">5</xref>). Although the pathophysiology of these disorders has not been fully understood, it seems that immunovirological factors should play major roles.</p><p>HTLV-1 infects 10-20 million people all over the world (<xref rid="R5" ref-type="bibr">5</xref>). It is endemic in parts of the worldincluding the Caribbean, parts of central Africa, Brazil, southern parts of the United States (<xref rid="R6" ref-type="bibr">6</xref>) and Northeast of Iran. Northeast of Iran is an endemic area for HTLV-1 and 2.1 percent of the residents of Mashhad, the largest city in northeast of Iran, are HTLV-1 carriers (<xref rid="R7" ref-type="bibr">7</xref>).</p><p>Studies have shown that less than five percent of HTLV-1 infected carriers develop HAM/TSP or ATL while about 95 percent remain asymptomatic carriers (<xref rid="R8" ref-type="bibr">8</xref>). Patients who develop ATL are often infected in childhood with a clinical latency period of 20-60 years; in contrast, HAM/TSP patients have shorter clinical latency periods (<xref rid="R9" ref-type="bibr">9</xref>). Typically, patients with HAM/TSP have more HTLV-1 infected lymphocytes than asymptomatic carriers (<xref rid="R10" ref-type="bibr">10</xref>, <xref rid="R11" ref-type="bibr">11</xref>).</p><p>A common reason for the pathogenesis of HTLV-1-associated diseases is T-cell growth activity and induction of T-cell proliferation by HTLV-1 transactivator (Tax) (<xref rid="R12" ref-type="bibr">12</xref>). Tax is a regulatory gene in HTLV-1 that is essential for cell transformation and replication. HTLV-1 transactivator encodes a phosphoprotein that increases HTLV-1 Long Terminal Repeat (LTR) transcription by activation of nuclear factors NF-&#x003ba;&#x003b2;. Tax does not bind directly to DNA fragments but activates other transcription factors such as NF-&#x003ba;&#x003b2; (<xref rid="R23" ref-type="bibr">23</xref>). It can activate many cell promoters such as promoters of IL-2, IL-2R, GM-CSF. Activation of these genes lead to continuous proliferation of HTLV-1 infected cells (<xref rid="R14" ref-type="bibr">14</xref>, <xref rid="R15" ref-type="bibr">15</xref>). It has been reported that expression of Tax mRNA is increased after culturing peripheral blood mononuclear cells from HAM/TSP patients (<xref rid="R16" ref-type="bibr">16</xref>, <xref rid="R17" ref-type="bibr">17</xref>).</p><p>HTLV-1 proviral load has been evaluated as predictor of HAM/TSP development. Some studies have shown that HTLV-1 proviral load is higher in HAM/TSP patients than in asymptomatic carriers (<xref rid="R18" ref-type="bibr">18</xref>, <xref rid="R19" ref-type="bibr">19</xref>). Although proviral load has possibly an important role in the development of HAM/TSP, association between this factor and the disease remains unclear (<xref rid="R23" ref-type="bibr">23</xref>) and it seems this index is not able to differentiate HTLV-I in latent phase. Therefore, it is estimated that assessment of proviral load along with Tax expression (an index of activity) should be a better indicator of developing HTLV-I associated diseases. In this study, the HTLV-1 Tax mRNA expression and proviral loads in PBMCs of HAM/TSP patients and asymptomatic carriers were evaluated in two different conditions, base line and activated cells (<xref rid="R20" ref-type="bibr">20</xref>).</p></sec><sec sec-type="materials|methods"><title>Material and Methods</title><sec><title>Subjects</title><p>The study was approved by the Ethics Committee of Tehran University of Medical Sciences. Patients were admitted to the Department of Neurology, Ghaem Hospital, Mashhad University of Medical Sciences (MUMS, Mashhad, Iran).</p><p>The patients had no history of previous treatment for HAM/TSP. Informed consents were obtained from the participants or their legal guardian at the first visit. The inclusion criterion was the definitive diagnosis of HAM/TSP according to the World Health Organization criteria (<xref rid="R21" ref-type="bibr">21</xref>-<xref rid="R24" ref-type="bibr">24</xref>). Thirty HAM/TSP patients, thirty HTLV-1 healthy carriers, and MT-2 cells were evaluated for HTLV-1 activity. Contamination of subjects with HTLV-1 were identified by serological methods and confirmed by PCR technique (<xref rid="R7" ref-type="bibr">7</xref>). MT-2 cell line is a human T-cell line that is infected with HTLV-1 (<xref rid="R25" ref-type="bibr">25</xref>, <xref rid="R26" ref-type="bibr">26</xref>).</p></sec><sec><title>Oligonucleotide designing and complementary DNA synthesis</title><p> Peripheral blood mononuclear cells (PBMCs) were isolated from EDTA-treated blood samples by Ficoll density gradient (Sigma, Germany). A quantitative real-time PCR assay (TaqMan method) was carried out to measure Tax expression and proviral load of HTLV-1 in PBMCs using specific primers and a fluorogenic probe by a Rotor Gene Q real-time PCR machine. RNA was extracted from fresh PBMCs using viral RNA extraction Mini Kit (Qiagen, Germany) and complementary DNA (cDNA) was synthesized using Revert Aid&#x02122; First Strand cDNA Synthesis Kit (Fermentas, Germany). Table <xref ref-type="table" rid="T1">1</xref> shows the nucleotide sequence of primers and probes. The procedure for conventional PCR was as followes: 1 &#x000b5;l cDNA (288 ng/&#x000b5;l), 2.5 &#x000b5;l reaction buffer 28x, 8.5 &#x000b5;l dNTP (10 mM, GeNet Bio), 2 &#x000b5;l MgCl<sub>2</sub> (25 mM, Fermentas), 0.5 &#x000b5;l each of primers (28 pM), 0.2 &#x000b5;l prime Taq DNA polymerase (5 U/&#x000b5;l, Fermentas), 12.8 &#x000b5;l distilled water. &#x003b2;<sub>2</sub>m was used as human housekeeping or reference gene in Tax expression measurement. The expression of this gene remains stable within PBMCs from samples (<xref rid="R27" ref-type="bibr">27</xref>).</p></sec><sec><title>Cell culture</title><p>After PBMCs isolation, the cells were washed with RPMI medium. Cells were then introduced into an enriched RPMI 1640 medium (containing 12% inactivated bovine serum albumin) in the presence of 1 mg /&#x000b5;l PMA (phorbol 22-myrestate13-acetate), 25 ng/ml ionomycin, and incubated in 5% CO2, 95% humidity for 6 hr. Afterwards, samples were collected for RNA extraction. Moreover, a cell line (MT-2) culture with ionomycin and PMA was used as control.</p></sec><sec><title>Real-time PCR</title><sec><title>HTLV-I Proviral Load</title><p>Peripheral blood mononuclear cells (PBMCs) were isolated from EDTA-treated blood samples by Ficoll density gradient (Sigma, Germany). DNA was extracted using Ge Net kit (Korea). To assess the HTLV-1 proviral load, a real-time TaqMan PCR absolute method was carried out using HTLV-1 RG kit (Novin Gene, Iran) (<xref rid="R28" ref-type="bibr">28</xref>). Briefly, the HTLV-1 copy number was referred to the actual amount of cellular DNA by quantifying albumin gene as the reference gene. HTLV-1and albumin DNA concentrations were calculated using two 5-point standard curves. The normalized value of the HTLV-1 proviral load was calculated as the ratio of (HTLV-1 DNA copies number /albumin DNA copies number/2) &#x000d7;10<sup>4</sup> and expressed as the number of HTLV-1 proviruses per 10<sup>4</sup> PBMCs (<xref rid="R7" ref-type="bibr">7</xref>).</p></sec><sec><title>Tax measurement</title><p>After cDNA synthesis, serial dilutions of standards (5 for each gene) were applied to relatively quantify the mRNA copy number of each single gene. Two standard curve methods were used for target and reference genes quantification by a Rotor Gene Q real-time PCR machine (Qiagen, Germany). The Rotor Gene 6000 software was used to analyze the standards and the unknown mRNA copy numbers. The relative quantity of each mRNA was normalized to the relative quantity of &#x003b2;<sub>2</sub>m mRNA. Then the relative Tax expression levels for each sample were calculated by an equation: Tax Normalized Index = copy number of gene of interest (Tax)/copy number of reference gene (&#x003b2;<sub>2</sub>m). Then the fold change in expression for each group was calculated by the following equation: mean of Tax normalized index of test group/ mean of Tax normalized index of healthy carriers.</p></sec></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Tax mRNA in HTLV-I infected subjects before stimulation of PBMCs</title><p>The HTLV-1 Tax mRNA load was measured in PBMCs of HAM/TSP patients and asymptomatic carriers (ACs). The mean &#x000b1; SEM of Tax mRNA load was 31.24&#x000b1;21.21 copies/ml in patients with HAM/TSP, while the value was 5.63&#x000b1;2.5 copies/ml in the ACs. An increase of 5.54-fold was observed in the patients group with HAM/TSP compared with the ACs, which was statistically insignificant (<italic>P</italic>=0.671, Mann Whitney).
</p></sec><sec><title>Tax mRNA load in HAM/TSP patients and ACs after stimulation of PBMCs </title><p>After isolating the PBMCs, the cells were treated with PMA and ionomycin for 6 hr, cDNA was synthesized, and real-time PCR performed. The treatment of T-cells infected with HTLV-1 resulted in the induction of Tax mRNA expression in the stimulated cells. Tax mRNA load was 2658&#x000b1;2005 copies/ml in HAM/TSP patients and it was 99.72&#x000b1;27.37 copies/ml in ACs. The expression level of Tax mRNA in the stimulated cells of HAM/TSP patients was 26.65 higher than ACs cells, which was statistically insignificant (<italic>P</italic>=0.042, Mann Whitney). Figure <xref ref-type="fig" rid="F1">1</xref>. Difference between Tax gene expression before and after cells stimulation was statistically significant (<italic>P</italic>=0.000, Wilcoxon's test).</p></sec><sec><title>Demographic results </title><p>HAM/TSP patients and control group showed no significant difference in gender (<italic>P</italic>=0.292) Figure <xref ref-type="fig" rid="F2">2</xref>. The mean of age in carriers was 42.15, and in patients was 45.04. Analyzing the data showed there was no significant difference between two groups in respect of age (<italic>P</italic>=0.34). It needs to be noted that the HTLV-1-associated diseases such as HAM/TSP and HTLV-1 infection are more prevalent in women than in men in Iran (<xref rid="R2" ref-type="bibr">2</xref>). No correlation was found between Tax mRNA expression and gender (Spearman's rho test). </p></sec><sec><title> Proviral load</title><p>Real-time PCR was performed on DNA that was extracted from peripheral blood mononuclear cells as previously described. Men and women were significantly different in proviral load (<italic>P</italic>=0.009). </p><p>Proviral load in patients was significantly higher than in carriers (<italic>P</italic>=0.004, Mann Whitney). The mean &#x000b1; SD proviral load in asymptomatic carriers was 460&#x000b1;153 copy/10<sup>4</sup> PBMCs and in patients with HAM/TSP was 2052&#x000b1;579 copy/10<sup>4</sup> PBMCs Table <xref ref-type="table" rid="T2">2</xref>. Results confirmed that proviral load in patients with HAM/TSP was 4.46 times higher than in asymptomatic carriers. To investigate the relationship between Tax gene expression and proviral load Spearman&#x02019;s rho test was used and there was a significant correlation between Tax mRNA expression in activated PBMCs and proviral load (R=%32, <italic>P</italic>=0.03).</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>A nationwide survey by Iranian Blood Transfusion Organization (IBTO) in 1996 and other epidemiological studies demonstrated that Razavi and north Khorasan and Golestan provinces in northeast of Iran are endemic for HTLV-I infection. These studies suggested that the highest prevalence of the virus was observed in Razavi Khorasan and southeast of Golestan provinces mainly in Mashhad, Neyshabour and Kalalah (<xref rid="R7" ref-type="bibr">7</xref>, <xref rid="R29" ref-type="bibr">29</xref>). Therefore the study of virus activities in Iran is an urgent priority.</p><p>In spite of the fact that HTLV-1 and its associated diseases such as ATLL and HAM/TSP were studied for several years, the pathogenesis of HTLV-1&#x02013;associated diseases and the interaction between virus, infected cells and the host immune system yet to be understood. Previous studies have provided evidence that T cell stimulation lead to viral protein expression in infected cells (<xref rid="R30" ref-type="bibr">30</xref>, <xref rid="R31" ref-type="bibr">31</xref>). HTLV-I Tax is one of such protein that can induce pro-inflammatory cytokine production, mainly IL-2, GM-CSF and IFN-&#x003b3;, in CD4<sup>+</sup> infected T cells (<xref rid="R32" ref-type="bibr">32</xref>). Pro-inflammatory cytokine production may affect on host immune responses results in forming inappropriate inflammatory reactions toward HAM/TSP (<xref rid="R29" ref-type="bibr">29</xref>). We have previously argued that the virological and host immune modulators might play the main roles in the pathophysiology of HAM/TSP (<xref rid="R2" ref-type="bibr">2</xref>).</p><p>This study showed that HTLV-I Tax mRNA expression dramatically increased in HAM/TSP patients compare to healthy carriers after <italic>in vitro</italic> PBMCs stimulation with PMA-ionomycine. However, Tax mRNA expression in HAM/TSP and healthy carriers in inactivated PBMCs did not show any diffrences.</p><p>This finding shows that HTLV-I infected T cells in HAM/TSP subjects maybe more sensitive to stimulatory signal and produces more Tax protein than healthy carries. Moreover, these changes in Tax expression, as the immune-dominant antigen, of HTLV-I infected CD4<sup>+</sup> cells make them more suitable to killing activities of specific CTLs too.</p><p>There are many controversial studies regarding the prognostic value of proviral load in healthy carriers or HAM/TSP patients. HTLV-I provirus load is generally higher in patients with HAM/TSP than ACs, however, there are ACs who have comparable HTLV-I proviral load with HAM/TSPs. Moreover, there have been conflicting reports on Tax expression and HAM/TSP progression. For instance, the results of a study indicated that Tax mRNA expression in HTLV-I&#x02013;infected cells of HAM/TSP subjects after 12hr culture did not show any differences with ACs with high proviral load. Whereas others demonstrated that the Tax mRNA expression in HTLV-I infected cells was higher in patients with HAM/TSP than in ACs (<xref rid="R33" ref-type="bibr">33</xref>, <xref rid="R34" ref-type="bibr">34</xref>).</p><p>Our study demonstrated that neither proviral load nor Tax in inactivated PBMCs are useful prognostic markers for monitoring of HTLV-I infected subjects. Tax expression may act as an index for viral activity and as an important index in predicting long-term status of HAM/TSP patients. The researchers still do not know why the small number of HTLV-I infected people develop associated diseases (<xref rid="R35" ref-type="bibr">35</xref>, <xref rid="R36" ref-type="bibr">36</xref>).</p><p>The finding of the present study indicated that proviral load in HAM/TSP patients was statistically higer than asymptomatic carriers (<italic>P</italic>=0.004). Although, Tax expression in inactivated PBMCs of HAM/TSP patients was more than asymptomatic carriers, it was not significant. Activated PBMCs of HAM/TSPs had 26.65 fold tax expressions than healthy carriers which was statistically meaningful. Therefore, if HTLV-I proviral load and Tax expression in activated PBMCs of HTLV-I infected individuals taken into account, they may act as a new strong prognostic index for monitoring of healthy carriers and HAM/TSP patients.</p><p>However, there are some limitations for this study; it can be assessed at the same time the HTLV-I HBZ expression as an important regulator of HTLV-I replication. Moreover, assessment of these viral protein and host immune response such as T cell population or T cell transcription factor make the study very strong.</p></sec><sec sec-type="conclusion"><title>Conclusion</title><p>Proviral load and Tax production in infected subjects are clearly affect on development of HTLV-I associated diseases (<xref rid="R37" ref-type="bibr">37</xref>, <xref rid="R38" ref-type="bibr">38</xref>). However, it seems that in the presence of T cell stimulatory signals the amount of Tax expression from infected CD4<sup>+</sup> cells is dramatically increase which may have two different effects, it makes these cells more susceptible to CTLs killing activities or induces pro-inflammatory cytokines production toward forming HTLV-I associated diseases.</p></sec></body><back><ack><title>Acknowledgment</title><p>This research has been supported by Tehran University of Medical Sciences and Mashhsd University of Medical Sciences research councils. We express our appreciation to the staff of inflammation research center in Mashhsd University of Medical Sciences for great help.</p></ack><ref-list><title>References</title><ref id="R1"><label>1</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Rezaee</surname><given-names>SA</given-names></name><name><surname>Fazly Bazzaz</surname><given-names>BS</given-names></name></person-group><article-title>The significance of HTLV-I in molecular oncology</article-title><source>Iran J Basic Med Sci</source><year>2013</year><volume>3</volume><fpage>178</fpage></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Rafatpanah</surname><given-names>H</given-names></name><name><surname>Rezaee</surname><given-names>A</given-names></name><name><surname>Etemadi</surname><given-names>M</given-names></name><name><surname>Farid</surname><given-names>Hossseini R</given-names></name><name><surname>Khorram</surname><given-names>B</given-names></name><name><surname>Afsahr</surname><given-names>L</given-names></name><etal/></person-group><article-title>The impact of interferon-alpha treatment on clinical and immunovirological aspects of HTLV-1 associated myelopathy in northeast of Iran</article-title><source>J Neuroimmunol</source><year>2012</year><volume>250</volume><fpage>87</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">22727800</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Franchini</surname><given-names>G</given-names></name></person-group><article-title>Molecular mechanisms of humanT-cell leukemia/ lymphotropic virus type I infection</article-title><source>Blood</source><year>1995</year><volume>86</volume><fpage>3619</fpage><lpage>3639</lpage><pub-id pub-id-type="pmid">7579327</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Vakili</surname><given-names>R</given-names></name><name><surname>Sabet</surname><given-names>F</given-names></name><name><surname>Ahmadi</surname><given-names>Ghezeldasht S</given-names></name><name><surname>Boostani</surname><given-names>R</given-names></name><name><surname>Rafatpanah</surname><given-names>H</given-names></name><name><surname>Shamsian</surname><given-names>A</given-names></name><etal/></person-group><article-title>Human T-lymphotropic virus type I (HTLV-I) proviral load and clinical features in Iranian HAM/TSP patients</article-title><source>Iran J Basic Med Sci</source><year>2013</year><volume>16</volume><fpage>268</fpage><lpage>272</lpage><pub-id pub-id-type="pmid">24470875</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Yakova</surname><given-names>M</given-names></name><name><surname>Lezin</surname><given-names>A</given-names></name><name><surname>Dantin</surname><given-names>F</given-names></name><name><surname>Lagathu</surname><given-names>G</given-names></name><name><surname>Olindo</surname><given-names>S</given-names></name><name><surname>Jean-Baptiste</surname><given-names>G</given-names></name><etal/></person-group><article-title>Increased proviral load in HTLV-1-infected patients with rheumatoid arthritis or connective tissue disease</article-title><source>Retrovirology</source><year>2005</year><volume>2</volume><fpage>4</fpage><pub-id pub-id-type="pmid">15686595</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Manns</surname><given-names>A</given-names></name><name><surname>Hisada</surname><given-names>M</given-names></name><name><surname>LaGrenade</surname><given-names>L</given-names></name></person-group><article-title>HumanT-lymphotropicvirus type I infection</article-title><source>Lancet</source><year>1999</year><volume>353</volume><fpage>1951</fpage><lpage>1958</lpage><pub-id pub-id-type="pmid">10371587</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Rafatpanah</surname><given-names>H</given-names></name><name><surname>Hedayati-Moghaddam</surname><given-names>MR</given-names></name><name><surname>Fathimoghadam</surname><given-names>F</given-names></name><name><surname>Bidkhori</surname><given-names>HR</given-names></name><name><surname>Shamsian</surname><given-names>SK</given-names></name><name><surname>Ahmadi</surname><given-names>S</given-names></name><name><surname>Sohgandi</surname><given-names>L</given-names></name><name><surname>Azarpazhooh</surname><given-names>MR</given-names></name><name><surname>Rezaee</surname><given-names>SA</given-names></name><name><surname>Farid</surname><given-names>R</given-names></name><name><surname>Bazarbachi</surname><given-names>A</given-names></name></person-group><article-title>High prevalence of HTLV-I infection in Mashhad, Northeast Iran: a population-based seroepidemiology survey</article-title><source>J Clin Virol</source><year>2011</year><month>11</month><volume>52</volume><fpage>172</fpage><lpage>176</lpage><pub-id pub-id-type="pmid">21840754</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Yamano</surname><given-names>Y</given-names></name><name><surname>Nagai</surname><given-names>M</given-names></name><name><surname>Brennan</surname><given-names>M</given-names></name><name><surname>Mora</surname><given-names>CA</given-names></name><name><surname>Soldan</surname><given-names>SS</given-names></name><name><surname>Tomaru</surname><given-names>U</given-names></name><etal/></person-group><article-title>Correlation of human T-cell lymphotropic virus type 1 (HTLV-1) mRNA with proviral DNA load, virus-specific CD8 T cells, and disease severity in&#x02212; HTLV-1 associated myelopathy (HAM/TSP)</article-title><source>Blood</source><year>2002</year><volume>99</volume><fpage>88</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">11756157</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Mortreux</surname><given-names>F</given-names></name><name><surname>Gabet</surname><given-names>AS</given-names></name><name><surname>Wattel</surname><given-names>E</given-names></name></person-group><article-title>Molecular and cellular aspects of HTLV-associated leukemo genesis <italic>in vivo</italic></article-title><source>Leukemia</source><year>2003</year><volume>17</volume><fpage>26</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">12529656</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Jacobson</surname><given-names>S</given-names></name><name><surname>Zaninovic</surname><given-names>V</given-names></name><name><surname>Mora</surname><given-names>C</given-names></name><name><surname>Rodgers-Johnson</surname><given-names>P</given-names></name><name><surname>Sheremata</surname><given-names>WA</given-names></name><name><surname>Gibbs</surname><given-names>CJ</given-names><suffix>Jr</suffix></name><etal/></person-group><article-title>Immunological findings in neurological diseases associated with antibodies to HTLV-I: activated lymphocytes in tropical spastic paraparesis</article-title><source>Ann Neurol</source><year>1988</year><volume>23</volume><fpage>S196</fpage><lpage>200</lpage><pub-id pub-id-type="pmid">2894814</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Jacobson</surname><given-names>S</given-names></name><name><surname>Gupta</surname><given-names>A</given-names></name><name><surname>Mattson</surname><given-names>D</given-names></name><name><surname>Mingioli</surname><given-names>E</given-names></name><name><surname>Mc-Farlin</surname><given-names>DE</given-names></name></person-group><article-title>Immunological studies intropical spastic paraparesis</article-title><source>Ann Neurol</source><year>1990</year><volume>27</volume><fpage>149</fpage><lpage>156</lpage><pub-id pub-id-type="pmid">2317010</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Nyborg</surname><given-names>JK</given-names></name><name><surname>Dynan</surname><given-names>WS</given-names></name></person-group><article-title>Interaction of cellular proteins with the human Tcell leukemi a virus type I transcriptional control region. Purification of cellular proteins that bind the 21-base pair repeat elements</article-title><source>J Biol Chem</source><year>1990</year><volume>265</volume><fpage>8230</fpage><lpage>8236</lpage><pub-id pub-id-type="pmid">2335523</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Masuda</surname><given-names>ES</given-names></name><name><surname>Imamura</surname><given-names>R</given-names></name><name><surname>Amasaki</surname><given-names>Y</given-names></name><name><surname>Arai</surname><given-names>K</given-names></name><name><surname>Arai</surname><given-names>N</given-names></name></person-group><article-title>Signalling in to the T-cell nucleus: NFAT regulation</article-title><source>Cell Signal</source><year>1998</year><volume>10</volume><fpage>599</fpage><lpage>611</lpage><pub-id pub-id-type="pmid">9794241</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Hatanaka</surname><given-names>M</given-names></name><name><surname>Kobayashi</surname><given-names>N</given-names></name></person-group><article-title>The pX region of HTLV-I</article-title><source>Princess Takamatsu Symp</source><year>1984</year><volume>15</volume><fpage>205</fpage><lpage>217</lpage><pub-id pub-id-type="pmid">6100640</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Bindhu</surname><given-names>M</given-names></name><name><surname>Nair</surname><given-names>A</given-names></name><name><surname>Lairmore</surname><given-names>MD</given-names></name></person-group><article-title>Role of accessory proteins of HTLV-1 in viral replication, T cell activation, and cellular gene expression</article-title><source>Front Biosci</source><year>2004</year><volume>9</volume><fpage>2556</fpage><lpage>2576</lpage><pub-id pub-id-type="pmid">15358581</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Pique</surname><given-names>C</given-names></name><name><surname>Dokhelar</surname><given-names>MC</given-names></name></person-group><article-title>
<italic>In vivo</italic> production of proteins of HTLV type1: evidence from cytotoxic Tlymphocytes</article-title><source>AIDS Res Hum Retroviruses</source><year>2000</year><volume>16</volume><fpage>1783</fpage><lpage>1786</lpage><pub-id pub-id-type="pmid">11080827</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Poiesz</surname><given-names>BJ</given-names></name><name><surname>Ruscetti</surname><given-names>FW</given-names></name><name><surname>Gazdar</surname><given-names>AF</given-names></name><name><surname>Bunn</surname><given-names>PA</given-names></name><name><surname>Minna</surname><given-names>JD</given-names></name><name><surname>Gallo</surname><given-names>RC</given-names></name></person-group><article-title>Detection and isolation of typeC retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneousT-cell lymphoma</article-title><source>Proc Natl Acad Sci USA</source><year>1980</year><volume>77</volume><fpage>7415</fpage><lpage>7419</lpage><pub-id pub-id-type="pmid">6261256</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Manns</surname><given-names>A</given-names></name><name><surname>Miley</surname><given-names>WJ</given-names></name><name><surname>Wilks</surname><given-names>RJ</given-names></name><name><surname>Morgan</surname><given-names>OS</given-names></name><name><surname>Hanchard</surname><given-names>B</given-names></name><name><surname>Wharfe</surname><given-names>G</given-names></name><etal/></person-group><article-title>Quantitative proviral DNA and antibody levels in the natural History of HTLV-1 infection</article-title><source>J Infect Dis</source><year>1999</year><volume>180</volume><fpage>1487</fpage><lpage>1493</lpage><pub-id pub-id-type="pmid">10515807</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Nagai</surname><given-names>M</given-names></name><name><surname>Usuku</surname><given-names>K</given-names></name><name><surname>Matsumoto</surname><given-names>W</given-names></name><name><surname>Kodama</surname><given-names>D</given-names></name><name><surname>Takenouchi</surname><given-names>N</given-names></name><name><surname>Moritoyo</surname><given-names>T</given-names></name><etal/></person-group><article-title>Analysis of HTLV-1 proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-1 carriers:high proviral load strongly predisposes to HAM/TSP</article-title><source>J Neurovirol</source><year>1998</year><volume>4</volume><fpage>586</fpage><lpage>593</lpage><pub-id pub-id-type="pmid">10065900</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Iwanaga</surname><given-names>M</given-names></name><name><surname>Watanabe</surname><given-names>T</given-names></name><name><surname>Utsunomiya</surname><given-names>T</given-names></name><name><surname>Okayama</surname><given-names>M</given-names></name><name><surname>Uchimaru</surname><given-names>K</given-names></name><name><surname>Koh</surname><given-names>KR</given-names></name><etal/></person-group><article-title>Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan</article-title><source>Blood</source><year>2010</year><volume>116</volume><fpage>1211</fpage><lpage>1219</lpage><pub-id pub-id-type="pmid">20448111</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Goncalves</surname><given-names>DU</given-names></name><name><surname>Proietti</surname><given-names>FA</given-names></name><name><surname>Barbosa</surname><given-names>Stancioli EF</given-names></name><name><surname>Martins</surname><given-names>ML</given-names></name><name><surname>Ribas</surname><given-names>JG</given-names></name><name><surname>Martins</surname><given-names>Filho OA</given-names></name><etal/></person-group><article-title>HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) inflammatory network</article-title><source>Inflamm Allergy Drug Targets</source><year>2008</year><volume>7</volume><fpage>98</fpage><lpage>107</lpage><pub-id pub-id-type="pmid">18691139</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Izumo</surname><given-names>S</given-names></name></person-group><article-title>Neuropathology of HTLV-1-associated myelopathy (HAM/TSP)</article-title><source>Neuropathology</source><year>2010</year><volume>30</volume><fpage>480</fpage></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Rios</surname><given-names>Grassi MF</given-names></name><name><surname>Olavarria</surname><given-names>VN</given-names></name><name><surname>Kruschewsky</surname><given-names>RdA</given-names></name><name><surname>Mascarenhas</surname><given-names>RE</given-names></name><name><surname>Dourado</surname><given-names>I</given-names></name><name><surname>Correia</surname><given-names>LCL</given-names></name><etal/></person-group><article-title>Human T Cell lymphotropic virus type 1 (HTLV-1) proviral load of HTLV-associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients according to new diagnostic criteria of HAM/TSP</article-title><source>J Med Virol</source><year>2011</year><volume>83</volume><fpage>1269</fpage><lpage>1274</lpage><pub-id pub-id-type="pmid">21567429</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Matsuura</surname><given-names>E</given-names></name><name><surname>Yamano</surname><given-names>Y</given-names></name><name><surname>Jacobson</surname><given-names>S</given-names></name></person-group><article-title>Neuroimmunity of HTLV-I Infection</article-title><source>J Neuroimmune Pharmacol</source><year>2010</year><volume>5</volume><fpage>310</fpage><lpage>325</lpage><pub-id pub-id-type="pmid">20437106</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Miyoshi</surname><given-names>I</given-names></name><name><surname>Kubonishi</surname><given-names>I</given-names></name><name><surname>Yoshimoto</surname><given-names>S</given-names></name><name><surname>Akagi</surname><given-names>T</given-names></name><name><surname>Ohtsuki</surname><given-names>Y</given-names></name><name><surname>Shiraishi</surname><given-names>Y</given-names></name><etal/></person-group><article-title>TypeC virus particles in acord T-cell line derived by co-cultivating normal human cord leukocytes and human leukaemic Tcells</article-title><source>Nature</source><year>1981</year><volume>294</volume><fpage>770</fpage><lpage>771</lpage><pub-id pub-id-type="pmid">6275274</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Poiesz</surname><given-names>BJ</given-names></name><name><surname>Ruscetti</surname><given-names>FW</given-names></name><name><surname>Gazdar</surname><given-names>AF</given-names></name><name><surname>Bunn</surname><given-names>PA</given-names></name><name><surname>Minna</surname><given-names>JD</given-names></name><name><surname>Gallo</surname><given-names>RC</given-names></name></person-group><article-title>Detection and isolation of typeC retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma</article-title><source>Proc Natl Acad Sci USA</source><year>1980</year><volume>77</volume><fpage>7415</fpage><lpage>7419</lpage><pub-id pub-id-type="pmid">6261256</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Dheda</surname><given-names>K</given-names></name><name><surname>Huggett</surname><given-names>JF</given-names></name><name><surname>Bustin</surname><given-names>SA</given-names></name><name><surname>Johnson</surname><given-names>MA</given-names></name><name><surname>Rook</surname><given-names>G</given-names></name><name><surname>Zumla</surname><given-names>A</given-names></name></person-group><article-title>Validation of housekeeping genes for normalizing RNA expression in real-time PCR</article-title><source>Biotechniques</source><year>2004</year><volume>37</volume><fpage>112</fpage><lpage>114</lpage><fpage>116</fpage><fpage>118</fpage><lpage>119</lpage><pub-id pub-id-type="pmid">15283208</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Dehee</surname><given-names>A</given-names></name><name><surname>Cesaire</surname><given-names>R</given-names></name><name><surname>Desire</surname><given-names>N</given-names></name><name><surname>Lezin</surname><given-names>A</given-names></name><name><surname>Bourdonne</surname><given-names>O</given-names></name><name><surname>Bera</surname><given-names>O</given-names></name><etal/></person-group><article-title>Quantification of HTLV-I proviral load by a TaqMan real-time PCR assay</article-title><source>J Virol Methods </source><year>2002</year><volume>102</volume><fpage>37</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">11879691</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Kalavi</surname><given-names>Kh</given-names></name><name><surname>Moradi</surname><given-names>A</given-names></name><name><surname>Tabarraei</surname><given-names>A</given-names></name></person-group><article-title>Population based sero prevalence of HTLV-I infection in Golestan Province, South East of Caspian Sea, Iran</article-title><source>Iran J Basic Med Sci</source><year>2013</year><volume>16</volume><fpage>225</fpage><lpage>228</lpage><pub-id pub-id-type="pmid">24470867</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>HC</given-names></name><name><surname>Dezzutti</surname><given-names>CS</given-names></name><name><surname>Lal</surname><given-names>RB</given-names></name><name><surname>Rabson</surname><given-names>AB</given-names></name></person-group><article-title>Activation of human T-cell leukemia virus type 1 tax gene expression in chronically infected T cells</article-title><source>J Virol</source><year>1998</year><volume>72</volume><fpage>6264</fpage><lpage>6270</lpage><pub-id pub-id-type="pmid">9621103</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>HC</given-names></name><name><surname>Hickey</surname><given-names>M</given-names></name><name><surname>Hsu</surname><given-names>L</given-names></name><name><surname>Medina</surname><given-names>D</given-names></name><name><surname>Rabson</surname><given-names>AB</given-names></name></person-group><article-title>Activation of human T cell leukemia virus type 1 LTR promoter and cellular promoter elements by T cell receptor signaling and HTLV-1 Tax expression</article-title><source>Virology</source><year>2005</year><volume>339</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">15964046</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>HC</given-names></name><name><surname>Charlene</surname><given-names>S</given-names></name><name><surname>Dezzutti</surname></name><name><surname>Renu</surname><given-names>B</given-names></name><name><surname>Lal</surname><given-names>A</given-names></name><name><surname>Rabson</surname><given-names>AB</given-names></name></person-group><article-title>Activation of Human T-Cell leukemia virus type 1 <italic>tax gene</italic> expression in chronically infected T Cells</article-title><source>J Virol</source><year>1998</year><volume>7</volume><fpage>6264</fpage><lpage>6270</lpage><pub-id pub-id-type="pmid">9621103</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Furukawa</surname><given-names>Y</given-names></name><name><surname>Saito</surname><given-names>M</given-names></name><name><surname>Matsumoto</surname><given-names>W</given-names></name><name><surname>Usuku</surname><given-names>K</given-names></name><name><surname>Tanaka</surname><given-names>Y</given-names></name><name><surname>Izumo</surname><given-names>S</given-names></name><etal/></person-group><article-title>Different cytokine production in tax-expressing cells between patients with human T cell lymphotropic virus type I (HTLV-I)&#x02013;associated myelopathy/tropical spastic paraparesis and asymptomatic HTLV-I carriers</article-title><source>J Infect Dis</source><year>2003</year><volume>187</volume><fpage>1116</fpage><lpage>1125</lpage><pub-id pub-id-type="pmid">12660926</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Best</surname><given-names>I</given-names></name><name><surname>Adaui</surname><given-names>V</given-names></name><name><surname>Verdonck</surname><given-names>K</given-names></name><name><surname>Gonz&#x000e1;lez</surname><given-names>E</given-names></name><name><surname>Tipismana</surname><given-names>M</given-names></name><name><surname>Clark</surname><given-names>D</given-names></name><etal/></person-group><article-title>2Proviral load and immune markers associated with human T-lymphotropic virus type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Peru</article-title><source>Clin Exp Immunol</source><year>2006</year><volume>146</volume><fpage>226</fpage><lpage>233</lpage><pub-id pub-id-type="pmid">17034574</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Barmak</surname><given-names>K</given-names></name><name><surname>Harhaj</surname><given-names>E</given-names></name><name><surname>Grant</surname><given-names>C</given-names></name><name><surname>Alefantis</surname><given-names>T</given-names></name><name><surname>Wigdahl</surname><given-names>B</given-names></name></person-group><article-title>Human T cell leukemia virus type I-induced disease: pathways to cancer and neurodegeneration</article-title><source>Virology</source><year>2003</year><volume>308</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">12706085</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Bangham</surname><given-names>CR</given-names></name><name><surname>Hall</surname><given-names>SE</given-names></name><name><surname>Jeffery</surname><given-names>KJ</given-names></name><name><surname>Vine</surname><given-names>AM</given-names></name><name><surname>Witkover</surname><given-names>A</given-names></name><name><surname>Nowak</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Genetic control and dynamics of the cellular immune response to the human T-cell leukaemia virus, HTLV-I</article-title><source>Philos Trans R Soc Lond B Biol Sci</source><year>1999</year><volume>354</volume><fpage>691</fpage><lpage>700</lpage><pub-id pub-id-type="pmid">10365395</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Akagi</surname><given-names>T</given-names></name><name><surname>Ono</surname><given-names>H</given-names></name><name><surname>Nyunoya</surname><given-names>H</given-names></name><name><surname>Shimotohno</surname><given-names>K</given-names></name></person-group><article-title>Characterization of peripheral blood T-lymphocytes transduced with HTLV-1 Tax mutants with different <italic>trans</italic>-activating phenotype</article-title><source>Oncogene</source><year>1997</year><volume>14</volume><fpage>2071</fpage><lpage>2078</lpage><pub-id pub-id-type="pmid">9160887</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Grassmann</surname><given-names>R</given-names></name><name><surname>Dengler</surname><given-names>C</given-names></name><name><surname>Muller-Fleckenstein</surname><given-names>I</given-names></name><name><surname>Fleckenstein</surname><given-names>B</given-names></name><name><surname>McGuire</surname><given-names>K</given-names></name><name><surname>Dokhelar</surname><given-names>MC</given-names></name><name><surname>Sodroski</surname><given-names>JG</given-names></name><name><surname>Haseltine</surname><given-names>WA</given-names></name></person-group><article-title>Transformation to continuous growth of primary human T lymphocytes by human T-cell leukemia virus type 1 X-region genes transduced by a herpesvirus saimiri vector</article-title><source>Proc Natl Acad Sci USA</source><year>1989</year><volume>86</volume><fpage>3351</fpage><lpage>3355</lpage><pub-id pub-id-type="pmid">2541443</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>mRNA Tax expression was assessed before and after activation with PMA and ionomycin. Tax markedly increased after activation in HAM/TSP patients (a) compared to carriers (b) Ionomycin and PMA were used as lymphocyte activators</p></caption><graphic xlink:href="IJBMS-17-531_F1"/></fig><fig id="F2" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>The gender distribution in HAM/TSP patients and carriers</p></caption><graphic xlink:href="IJBMS-17-531_F2"/></fig><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1.</label><caption><p>The nucleotide sequence of specific primers and probes for HTLV-I Tax and Beta 2- Microglobulin</p></caption><table frame="hsides" rules="none" width="100%"><tbody><tr><td colspan="2" rowspan="1">HTLV-I Tax:</td></tr><tr><td rowspan="1" colspan="1">The forward primer: </td><td rowspan="1" colspan="1">
<italic>(5096-5115)</italic><italic>; </italic><italic>5</italic><italic>&#x02032;</italic><italic>-ATCCCGTGGAGACTCCTCAA-3</italic><italic>&#x02032;</italic></td></tr><tr><td rowspan="1" colspan="1">The reverse primer: </td><td rowspan="1" colspan="1"> (<italic>5180-5183, 7302-7312); 5</italic><italic>&#x02032;</italic><italic>-</italic><italic>CCTGGGAAGTGGGCCATG</italic><italic>-3</italic><italic>&#x02032;</italic></td></tr><tr><td rowspan="1" colspan="1">The probe: </td><td rowspan="1" colspan="1">
<italic>(5123-5145); 5</italic><italic>&#x02032;</italic><italic>-</italic><italic>CATGCCCAAGACCCGTCGGAGG</italic><italic>-3</italic><italic>&#x02032;</italic></td></tr><tr><td colspan="2" rowspan="1">Beta 2- Microglobulin</td></tr><tr><td rowspan="1" colspan="1">The forward primer: </td><td rowspan="1" colspan="1"><italic>TTGTCTTTCAGCAAGGACTGG</italic></td></tr><tr><td rowspan="1" colspan="1">The reverse primer: </td><td rowspan="1" colspan="1"><italic>CCACTTAACTATCTTGGGCTGTG</italic></td></tr><tr><td rowspan="1" colspan="1">The probe: </td><td rowspan="1" colspan="1"><italic>TCACATGGTTCACACGGCAGGCAT</italic></td></tr></tbody></table></table-wrap><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2.</label><caption><p>Laboratory findings in HAM/TSP patients and carriers</p></caption><table frame="hsides" rules="none" width="100%"><thead><tr><th align="left" rowspan="1" colspan="1">Characteristics</th><th rowspan="1" colspan="1">Asymptomatic carriers</th><th rowspan="1" colspan="1">HAM/TSP patients</th><th rowspan="1" colspan="1">
<italic>P</italic>-value</th></tr><tr><th colspan="4" rowspan="1">
<hr/>
</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">HTLV-1 Proviral load/10<sup>4</sup> PBMCs</td><td align="center" rowspan="1" colspan="1">460&#x000b1;153</td><td align="center" rowspan="1" colspan="1">2052&#x000b1;579</td><td align="center" rowspan="1" colspan="1">0.004</td></tr><tr><td rowspan="1" colspan="1">Tax expression copy/ml (before stimulation)</td><td align="center" rowspan="1" colspan="1">5.63&#x000b1;2.5</td><td align="center" rowspan="1" colspan="1">31.24&#x000b1;21.21</td><td align="center" rowspan="1" colspan="1">0.671</td></tr><tr><td rowspan="1" colspan="1">Tax expression copy/ml (after stimulation)</td><td align="center" rowspan="1" colspan="1">99.72&#x000b1;27.37</td><td align="center" rowspan="1" colspan="1">2658&#x000b1;2005</td><td align="center" rowspan="1" colspan="1">0.042</td></tr></tbody></table></table-wrap></floats-group></article>
